EGFR and non-small cell lung carcinoma: Mobocertinib is now FDA approved for pretreated patients with advanced-stage NSCLC bearing EGFR exon 20 insertions, and trials comparing mobocertinib and platinum-based chemotherapy as first line treatments are currently ongoing (e.g., EXCLAIM-2 NCT04129502).